TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17927499

Group type: EXPERIMENTAL
Intervention: Higher dietary beta carotene intake
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Higher plasma beta carotene levels
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Alpha tocopherol
Number of subjects: 540
Study: 15738352

Group type: EXPERIMENTAL
Intervention: 600 mg clopidogrel with eptifibatide
Number of subjects: 120

Group type: COMPARATOR
Intervention: 600 mg clopidogrel without eptifibatide
Number of subjects: 120

Group type: COMPARATOR
Intervention: 300 mg clopidogrel without eptifibatide
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: eptifibatide
Number of subjects: 120
Study: 11930332

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (10,000 IU of retinyl palmitate)
Number of subjects: 400
Study: 9452835

Group type: EXPERIMENTAL
Intervention: Sickle cell anemia patients
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Girls with sickle cell anemia
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Boys with sickle cell anemia
Number of subjects: 25
Study: 7657850

Group type: EXPERIMENTAL
Intervention: 200-mg oral controlled-release morphine sulfate tablet with naltrexone blockade
Number of subjects: 23

Group type: COMPARATOR
Intervention: two 100-mg MSC tablets
Number of subjects: 23
Study: 2675301

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Antacid
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study: 48053

Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control anaesthetic (fiben using halothane-free apparatus)
Number of subjects: 76
Study: 31651289

Group type: EXPERIMENTAL
Intervention: Snacking before bed
Number of subjects: 1004

Group type: COMPARATOR
Intervention: Watching TV
Number of subjects: 1004

Group type: COMPARATOR
Intervention: Sleeping during leisure periods
Number of subjects: 1004

Group type: COMPARATOR
Intervention: Bicycling as a means of transport to school
Number of subjects: 1004
Study: 28703903

Group type: EXPERIMENTAL
Intervention: Nemolizumab 0.1 to 3 mg/kg as a single dose once every 4 weeks or 2 mg/kg once every 8 weeks
Number of subjects: 299

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 299
Study: 25891232

Group type: EXPERIMENTAL
Intervention: Heavy drinking in the past 30 days
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: No alcohol use in the past 30 days
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Daily or nearly daily drinking
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Factors associated with frequency of alcohol consumption
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Frequent heavy drinking, alcohol abuse/dependence, and unprotected sex under the influence of alcohol
Number of subjects: 278
Study: 23899425

Group type: EXPERIMENTAL
Intervention: Survey of Organizational Attributes in Primary Care (SOAPC)
Number of subjects: 178
Study: 21251985

Group type: EXPERIMENTAL
Intervention: Tanezumab 50μg/kg administered on Days 1 and 56 with subsequent doses at 8-week intervals (up to a total of eight infusions)
Number of subjects: 281
Study: 19117313

Group type: EXPERIMENTAL
Intervention: EMLA Cream (EC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (lubricant ointment)
Number of subjects: 30
Study: 17762314

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Carbamazepine (CBZ)
Number of subjects: 64
Study: 15247553

Group type: EXPERIMENTAL
Intervention: Atazanavir 400 mg once daily
Number of subjects: 810

Group type: COMPARATOR
Intervention: Efavirenz 600 mg once daily
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: Atazanavir
Number of subjects: 810

Group type: COMPARATOR
Intervention: Efavirenz
Number of subjects: 810
Study: 15011220

Group type: EXPERIMENTAL
Intervention: Standard advanced cardiac life support (ACLS) intervention with early empiric administration of bicarbonate (1-mEq/kg dose)
Number of subjects: 874

Group type: COMPARATOR
Intervention: Standard advanced cardiac life support (ACLS) intervention without early empiric administration of bicarbonate
Number of subjects: 874
Study: 11426094

Group type: EXPERIMENTAL
Intervention: ondansetron 4 mg intravenously at the time of dural closure
Number of subjects: 170

Group type: COMPARATOR
Intervention: saline placebo
Number of subjects: 170
Study: 9437202

Group type: EXPERIMENTAL
Intervention: Cholesterol-lowering therapies
Number of subjects: 16
Study: 8290902

Group type: EXPERIMENTAL
Intervention: Cefpirome 1 g bid
Number of subjects: 865

Group type: COMPARATOR
Intervention: Ceftazidime 1 g bid
Number of subjects: 865

Group type: EXPERIMENTAL
Intervention: Cefpirome 2 g bid
Number of subjects: 865

Group type: COMPARATOR
Intervention: Ceftazidime 2 g bid
Number of subjects: 865

Group type: COMPARATOR
Intervention: Ceftazidime 2 g tid
Number of subjects: 865

Group type: COMPARATOR
Intervention: Ceftriaxone 1 g bid
Number of subjects: 865

Group type: EXPERIMENTAL
Intervention: Cefpirome
Number of subjects: 865

Group type: COMPARATOR
Intervention: Comparators
Number of subjects: 865
Study: 3326634

Group type: EXPERIMENTAL
Intervention: Pindolol, 10 mg twice daily
Number of subjects: 10

Group type: COMPARATOR
Intervention: Propranolol, 80 mg three times daily
Number of subjects: 10
Study: 28967549

Group type: EXPERIMENTAL
Intervention: Methotrexate 15 mg/wk
Number of subjects: 97

Group type: COMPARATOR
Intervention: Cyclosporine 2.5 mg/kg/d
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Methotrexate 25 mg/wk (after dose increase)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Cyclosporine (after dose increase)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 97
Study: 25393089

Group type: EXPERIMENTAL
Intervention: Systemic steroid therapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Thermal therapy (sulphurous water insufflation)
Number of subjects: 80
Study: 24796484

Group type: EXPERIMENTAL
Intervention: sunitinib
Number of subjects: 321
Study: 23611571

Group type: EXPERIMENTAL
Intervention: 200 μg INFS (Treatment A)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 400 μg INFS (Treatment B)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 400 μg INFS (Treatment C)
Number of subjects: 20
Study: 21044931

Group type: EXPERIMENTAL
Intervention: Non-absorbable interrupted sutures (NA)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Absorbable continuous sutures (A)
Number of subjects: 198
Study: 18223286

Group type: EXPERIMENTAL
Intervention: CD8-depleted peripheral blood stem cells
Number of subjects: 50

Group type: COMPARATOR
Intervention: Non-manipulated peripheral blood stem cells
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: CD8-depleted and non-manipulated peripheral blood stem cells
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Factors associated with high sjTREC concentration
Number of subjects: 50
Study: 16306217

Group type: EXPERIMENTAL
Intervention: Heat stress
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Cooling
Number of subjects: 17

Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 17
Study: 14620118

Group type: EXPERIMENTAL
Intervention: Crowned teeth
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control teeth (no restorations)
Number of subjects: 11
Study: 10876973

Group type: EXPERIMENTAL
Intervention: Product A (Decortil lipocrema IDI Farmaceutici)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Product B (Decortil crema, IDI Farmaceutici)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Product C (Lichtena AI crema UCB Pharma)
Number of subjects: 30
Study: 8701045

Group type: EXPERIMENTAL
Intervention: artesunate 600 mg followed by mefloquine 500 mg
Number of subjects: 153

Group type: COMPARATOR
Intervention: mefloquine 1000 mg
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Combination of artesunate and mefloquine
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: artesunate alone
Number of subjects: 153
Study: 1735009

Group type: EXPERIMENTAL
Intervention: Cisplatin (DDP) 37.5 mg/m2 (regimens A and B) or 75 mg/m2 (regimens C and D) + Hexamethylmelamine (HMM) 200 mg/m2 orally daily on days 8‐21
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Cisplatin (DDP) + Hexamethylmelamine (HMM)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Pyridoxine 300 mg/m2 orally on Days 1‐21 (regimens B and D)
Number of subjects: 248
Study: 6547795

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy (specific type not mentioned)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-treated control group
Number of subjects: 0
Study: 31292932

Group type: EXPERIMENTAL
Intervention: Cognitive task (counting backward from a randomly chosen three-digit number)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Light finger touch contact
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Vision available vs. not available
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Finger touch and cognitive task simultaneously
Number of subjects: 15
Study: 30782764

Group type: EXPERIMENTAL
Intervention: ToyBox obesity prevention intervention; details on dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group; details not specified
Number of subjects: 0
Study: 28681171

Group type: EXPERIMENTAL
Intervention: R/D/E (ridaforolimus 10 mg QD 5 ×/week, dalotuzumab 10 mg/kg/week, exemestane 25 mg/day)
Number of subjects: 80

Group type: COMPARATOR
Intervention: R/E (ridaforolimus 30 mg QD 5 ×/week, exemestane 25 mg/day)
Number of subjects: 80

Group type: COMPARATOR
Intervention: R/E
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: R/D/E
Number of subjects: 80
Study: 26426556

Group type: EXPERIMENTAL
Intervention: Laerdal Skill Reporter (LSR)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Philips MRx Q-CPR
Number of subjects: 15
Study: 23422465

Group type: EXPERIMENTAL
Intervention: Immediate 20-week biweekly gym training programme
Number of subjects: 32

Group type: COMPARATOR
Intervention: Delayed 10-week gym training programme starting 10 weeks later
Number of subjects: 32
Study: 21555815

Group type: EXPERIMENTAL
Intervention: Drug Conservation (DC) arm
Number of subjects: 2248

Group type: COMPARATOR
Intervention: Viral Suppression (VS) arm
Number of subjects: 2248

Group type: EXPERIMENTAL
Intervention: Currently anaemic patients
Number of subjects: 2248
Study: 19617601

Group type: EXPERIMENTAL
Intervention: Percutaneous left ventricular assist devices (LVADs)
Number of subjects: 2

Group type: COMPARATOR
Intervention: TandemHeart
Number of subjects: 2
Study: 18236200

Group type: EXPERIMENTAL
Intervention: Spaced Retrieval (SR) training
Number of subjects: 38

Group type: COMPARATOR
Intervention: Didactic strategy instruction (SI)
Number of subjects: 38
Study: 15169576

Group type: EXPERIMENTAL
Intervention: Combination of r-hFSH and r-hLH (2:1 ratio)
Number of subjects: 231

Group type: COMPARATOR
Intervention: r-hFSH alone
Number of subjects: 231
Study: 12177098

Group type: EXPERIMENTAL
Intervention: Fulvestrant 250 mg once monthly
Number of subjects: 400

Group type: COMPARATOR
Intervention: Anastrozole 1 mg daily
Number of subjects: 400
Study: 9875582

Group type: EXPERIMENTAL
Intervention: Four-drug oral regimen (Rifampin 10 mg/kg daily, Ciprofloxacin 500 mg twice daily, Clofazimine 100 mg every day, Ethambutol 15 mg/kg daily) + Amikacin 10 mg/kg intravenously or intramuscularly 5 days weekly for the first 4 weeks
Number of subjects: 74

Group type: COMPARATOR
Intervention: Four-drug oral regimen (Rifampin 10 mg/kg daily, Ciprofloxacin 500 mg twice daily, Clofazimine 100 mg every day, Ethambutol 15 mg/kg daily)
Number of subjects: 74
Study: 7597661

Group type: EXPERIMENTAL
Intervention: Eformoterol 24 micrograms twice daily
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo twice daily
Number of subjects: 16
Study: 2348454

Group type: EXPERIMENTAL
Intervention: Whirlpool baths
Number of subjects: 40

Group type: COMPARATOR
Intervention: Warm baths
Number of subjects: 40
Study: 88330

Group type: EXPERIMENTAL
Intervention: Checkerboard pattern displacement (red, green, blue)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Colour stimulation (red, green, blue)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Luminance measurement
Number of subjects: 0
Study: 6357209

Group type: EXPERIMENTAL
Intervention: suprofen 400 mg
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: suprofen 200 mg
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: ASA 650 mg + codeine 60 mg
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: ASA 650 mg
Number of subjects: 196

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 196
Study: 31078486

Group type: EXPERIMENTAL
Intervention: FIT-HIP intervention (multicomponent cognitive behavioral intervention conducted by physiotherapists)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: FIT-HIP intervention
Number of subjects: 78

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 78
Study: 27530927

Group type: EXPERIMENTAL
Intervention: Early cholecystectomy
Number of subjects: 72

Group type: COMPARATOR
Intervention: Delayed cholecystectomy
Number of subjects: 72
Study: 27428506

Group type: EXPERIMENTAL
Intervention: Imiquimod
Number of subjects: 30

Group type: COMPARATOR
Intervention: Laser vaporisation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 30
Study: 24639418

Group type: EXPERIMENTAL
Intervention: Application of sunscreen
Number of subjects: 2

Group type: COMPARATOR
Intervention: High sun exposure (Monegasque)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Low sun exposure (Berlin)
Number of subjects: 2
Study: 21278165

Group type: EXPERIMENTAL
Intervention: Music intervention (10-min exposure to relaxing music through headphones)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (no music intervention)
Number of subjects: 140
Study: 20194044

Group type: EXPERIMENTAL
Intervention: Co-trimoxazole (CTM) 48 mg/kg/day divided into two doses for 1 month
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo for 1 month
Number of subjects: 46
Study: 19089226

Group type: EXPERIMENTAL
Intervention: Fibrin adhesive derived from snake venom
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sutured grafts (control group)
Number of subjects: 15
Study: 14685867

Group type: EXPERIMENTAL
Intervention: Bovine colostrum (BC) 60 g.day(‐1)
Number of subjects: 13
Study: 11395670

Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg
Number of subjects: 461

Group type: COMPARATOR
Intervention: Lansoprazole 30 mg
Number of subjects: 461
Study: 9262268

Group type: EXPERIMENTAL
Intervention: HCG (5000 IU) after Dexamethasone administration
Number of subjects: 23
Study: 8498665

Group type: EXPERIMENTAL
Intervention: 1% ropivacaine
Number of subjects: 44

Group type: COMPARATOR
Intervention: 0.75% bupivacaine
Number of subjects: 44
Study: 3434739

Group type: EXPERIMENTAL
Intervention: 5% hyperbaric lignocaine
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0.5% hyperbaric bupivacaine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 20
Study: 28926636

Group type: EXPERIMENTAL
Intervention: Per-unit dispensing of antibiotics (experimental group)
Number of subjects: 1185

Group type: COMPARATOR
Intervention: Traditional pre-packed boxes of antibiotics (control group)
Number of subjects: 1185
Study: 27188987

Group type: COMPARATOR
Intervention: Low AKG content (LAC, 10 mg AKGs)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: High AKG content (HAC, 20 mg AKGs)
Number of subjects: 26
Study: 25202816

Group type: EXPERIMENTAL
Intervention: BMI < 18.5 kg/m2
Number of subjects: 2620

Group type: COMPARATOR
Intervention: BMI 18.5-24.9 kg/m2
Number of subjects: 2620

Group type: COMPARATOR
Intervention: BMI ≥ 18.5 kg/m2
Number of subjects: 2620
Study: 21987579

Group type: EXPERIMENTAL
Intervention: Cataract surgery after trabeculectomy
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Cataract surgery performed 6 months after trabeculectomy
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Cataract surgery performed 1 year after trabeculectomy
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Cataract surgery performed 2 years after trabeculectomy
Number of subjects: 235
Study: 19161045

Group type: EXPERIMENTAL
Intervention: ERr 731
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 17211062

Group type: EXPERIMENTAL
Intervention: Silver fiber-containing compression stockings
Number of subjects: 10

Group type: COMPARATOR
Intervention: Regular hosiery
Number of subjects: 10
Study: 15882526

Group type: EXPERIMENTAL
Intervention: dTpa-IPV vaccine
Number of subjects: 806

Group type: COMPARATOR
Intervention: dTpa+IPV vaccine
Number of subjects: 806

Group type: COMPARATOR
Intervention: Td-IPV vaccine
Number of subjects: 806
Study: 11211195

Group type: EXPERIMENTAL
Intervention: IVIg (500 mg/kg/day for 7 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Monoclonal anti-CD3 (OKT3, 5 mg/day for 14 days)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: IVIg
Number of subjects: 30

Group type: COMPARATOR
Intervention: OKT3
Number of subjects: 30
Study: 10083972

Group type: EXPERIMENTAL
Intervention: bupivacaine (0.5%) with adrenaline (1:200,000)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: bupivacaine (0.5%)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: normal saline with adrenaline (1:200,000)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: normal saline
Number of subjects: 100

Group type: COMPARATOR
Intervention: no infiltration (control group)
Number of subjects: 100
Study: 7522124

Group type: EXPERIMENTAL
Intervention: Postoperative radiation therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined postoperative radiation and chemotherapy
Number of subjects: 0
Study: 3406681

Group type: EXPERIMENTAL
Intervention: Intellectual Function Training (IFT) plus a regular rehabilitation programme (R) (n = 15)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Intellectual Housework Training (IHT) plus R (n = 19)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: IFT + IHT + R (n = 15)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Regular rehabilitation only (R) (n = 18)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Generalization gains in 4/5 'theoretical' intellectual functional areas assessed with IFA
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Generalization gains in 3/7 'practical' intellectual functional areas assessed with IHA
Number of subjects: 67
Study: 31408192

Group type: EXPERIMENTAL
Intervention: Families on Track (FOT) intervention
Number of subjects: 30

Group type: COMPARATOR
Intervention: Active comparison group
Number of subjects: 30
Study: 28803087

Group type: EXPERIMENTAL
Intervention: Fentanyl buccal tablet (FBT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 26068323

Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg.kg‐1)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 25605189

Group type: EXPERIMENTAL
Intervention: Intravenous flurbiprofen axetil and opioids
Number of subjects: 120

Group type: COMPARATOR
Intervention: Morphine sulfate sustained-release tablets
Number of subjects: 120
Study: 22066559

Group type: EXPERIMENTAL
Intervention: PFC prosthesis
Number of subjects: 82

Group type: COMPARATOR
Intervention: CKS prosthesis
Number of subjects: 82
Study: 18976733

Group type: EXPERIMENTAL
Intervention: Immediate circumcision
Number of subjects: 1608

Group type: COMPARATOR
Intervention: Delayed circumcision (control)
Number of subjects: 1608
Study: 17705186

Group type: EXPERIMENTAL
Intervention: Lamivudine therapy
Number of subjects: 486
Study: 15172863

Group type: EXPERIMENTAL
Intervention: 10-mL 1% lidocaine infusion
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 10 minutes after lidocaine infusion
Number of subjects: 80
Study: 11508185

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT)
Number of subjects: 27
Study: 9790153

Group type: EXPERIMENTAL
Intervention: Alprazolam 0.125 mg twice a day
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 7658064

Group type: EXPERIMENTAL
Intervention: Rhesus rotavirus monovalent reassortant vaccine (10^4 pfu)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Tetravalent vaccine (10^4 pfu)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 2651924

Group type: EXPERIMENTAL
Intervention: Ranitidine, 150 mg nightly
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 1132949

Group type: EXPERIMENTAL
Intervention: 20 mg Primperan (20 mg metoclopramide, Lundbeck)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 20 mg Metopram (20 mg metoclopramide, Leiras)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Physiological saline (control group)
Number of subjects: 45
Study: 31090170

Group type: EXPERIMENTAL
Intervention: Telbivudine (LdT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Entecavir (ETV)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both LdT and ETV
Number of subjects: 60
Study: 30736781

Group type: EXPERIMENTAL
Intervention: 12-week RUFIT-NZ intervention
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 96
Study: 28499715

Group type: EXPERIMENTAL
Intervention: Micronutrient supplements in infancy
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Serum anti‐flagellin IgA concentration at 6 weeks
Number of subjects: 113
Study: 26310979

Group type: EXPERIMENTAL
Intervention: Home-based intervention (HBI)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Specialized clinic-based intervention (CBI)
Number of subjects: 280
Study: 22749947

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate (4 g over 15 minutes followed by 16 g over 24 hours)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study: 20561173

Group type: EXPERIMENTAL
Intervention: Home set-up polysomnography (PSG)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Laboratory-based PSG
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Home set-up PSG
Number of subjects: 30
Study: 19910811

Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 50
Study: 17317046

Group type: EXPERIMENTAL
Intervention: Transdermal E2/NETA (25 microg E2 and 125 microg NETA applied every 3-4 days)
Number of subjects: 677

Group type: COMPARATOR
Intervention: Oral E2/NETA (1 mg E2 and 0.5 mg NETA given daily)
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: Transdermal E2/NETA
Number of subjects: 677

Group type: COMPARATOR
Intervention: Oral E2/NETA
Number of subjects: 677